Arctic Therapeutics secures $21.5 million in funding round
Icelandic pharmaceutical developer Arctic Therapeutics has raised $21.5 million in an oversubscribed financing round led by Pekron and other institutional investors.
Arctic Therapeutics has successfully closed a $21.5 million financing round, exceeding initial targets due to high investor interest. The round was led by Pekron, with participation from the Sanos Group, Kaldbakur, and Landvættir, an Icelandic venture capital fund managed by AxUM Securities.
The capital injection is earmarked for the advancement of the company’s pharmaceutical development pipeline. By securing these funds, the firm aims to move its research projects through the next critical phases of clinical trials and preclinical testing.
This funding marks a significant milestone for the Reykjavik-based biotechnology company, which focuses on developing therapeutics for underserved patient populations. The presence of both international and Icelandic institutional investors underscores continued interest in Northern European biotech ventures as they transition from discovery to clinical validation.